
Paratek Pharmaceuticals PRTK
Quartalsbericht 2023-Q2
hinzugefügt 03.08.2023
Paratek Pharmaceuticals Gesamtes Eigenkapital 2011-2026 | PRTK
Gesamtes Eigenkapital Jährlich Paratek Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -171 M | -128 M | -102 M | -39.6 M | 47.6 M | 82.5 M | 71.6 M | 101 M | 95.2 M | -114 M | -113 M | 65.8 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 101 M | -171 M | -17 M |
Gesamtes Eigenkapital Vierteljährlich Paratek Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -201 M | -189 M | -171 M | -166 M | -149 M | -140 M | -128 M | -105 M | -99.3 M | -119 M | -102 M | -102 M | -102 M | -102 M | -39.6 M | -39.6 M | -39.6 M | -39.6 M | 47.6 M | 47.6 M | 47.6 M | 47.6 M | 82.5 M | 82.5 M | 82.5 M | 82.5 M | 71.6 M | 71.6 M | 71.6 M | 71.6 M | 101 M | 101 M | 101 M | 101 M | 95.2 M | 95.2 M | 95.2 M | 95.2 M | -114 M | 71.7 M | 71.7 M | 71.7 M | -113 M | 95.4 M | 95.4 M | 95.4 M | 65.8 M | 65.8 M | 65.8 M | 65.8 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 101 M | -201 M | 1.87 M |
Gesamtes Eigenkapital anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtes Eigenkapital | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | ||
|
Verastem
VSTM
|
57.2 M | $ 5.04 | -4.73 % | $ 349 M | ||
|
Voyager Therapeutics
VYGR
|
196 M | $ 3.96 | -4.12 % | $ 232 M | ||
|
VistaGen Therapeutics
VTGN
|
70.4 M | $ 0.57 | -5.87 % | $ 17.6 M | ||
|
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | ||
|
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | ||
|
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | ||
|
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | ||
|
Aileron Therapeutics
ALRN
|
16.9 M | - | 10.36 % | $ 9.8 M | ||
|
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M | ||
|
Arena Pharmaceuticals
ARNA
|
673 M | - | -6.81 % | $ 3.04 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | ||
|
Avenue Therapeutics
ATXI
|
2.8 M | - | -52.27 % | $ 4.45 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | ||
|
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
195 M | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | ||
|
Avid Bioservices
CDMO
|
60.9 M | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
219 M | $ 12.41 | -11.1 % | $ 1.88 B | ||
|
Wave Life Sciences Ltd.
WVE
|
518 M | $ 6.37 | 2.66 % | $ 1.07 B | ||
|
Xenetic Biosciences
XBIO
|
7.4 M | $ 2.72 | -2.86 % | $ 4.63 M | ||
|
XBiotech
XBIT
|
140 M | $ 2.27 | -1.73 % | $ 69.2 M | ||
|
Xenon Pharmaceuticals
XENE
|
755 M | $ 54.48 | -1.89 % | $ 4.24 B | ||
|
Xeris Pharmaceuticals
XERS
|
13.7 M | $ 5.4 | -3.05 % | $ 866 M | ||
|
X4 Pharmaceuticals
XFOR
|
186 M | $ 4.04 | -6.26 % | $ 171 M | ||
|
Xencor
XNCR
|
636 M | $ 11.42 | -7.23 % | $ 848 M | ||
|
XOMA Corporation
XOMA
|
83.9 M | $ 30.17 | -1.18 % | $ 364 M | ||
|
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B | ||
|
22nd Century Group
XXII
|
15.8 M | $ 2.41 | -18.03 % | $ 444 K | ||
|
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
57.1 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
286 M | - | - | $ 3.74 B | ||
|
Zai Lab Limited
ZLAB
|
716 M | $ 18.0 | 2.8 % | $ 19.7 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
23.6 M | $ 1.05 | -3.67 % | $ 21.5 M | ||
|
Enochian Biosciences
ENOB
|
-21.3 M | - | - | $ 40.5 M |